摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(2R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione

中文名称
——
中文别名
——
英文名称
1-[(2R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
英文别名
——
1-[(2R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione化学式
CAS
——
化学式
C10H14N2O6
mdl
——
分子量
258.23
InChiKey
DWRXFEITVBNRMK-WJZMDOFJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.6
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    119
  • 氢给体数:
    4
  • 氢受体数:
    6

文献信息

  • Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties
    申请人:Barai N. Vladimir
    公开号:US20070065922A1
    公开(公告)日:2007-03-22
    Purine N 9 -β-D-nucleosides containing 3-amino-3-deoxy-β-D-ribofaranose, 3-amino-2,3-dideoxy-β-D-ribofuranose, and 2-amino-2-deoxy-β-D-ribofuranose as sugar moieties are synthesized by biocatalytic transglycosylation of purine bases and the respective 3′-amino-3′-deoxyuridine, 3′-amino-3′-deoxythymidine and 2′-amino-2′-deoxyuridine as donors of the carbohydrate moiety, and the cells of Escherichia coli as a biocatalyst or glutaraldehyde (GA) treated cells of Escherichia coli as a biocatalyst or a mixture of thymidine (uridine) phosphorylase and purine nucleoside phosphorylase.
    含有3-氨基-3-脱氧-β-D-核糖呋喃糖,3-氨基-2,3-二脱氧-β-D-核糖呋喃糖和2-氨基-2-脱氧-β-D-核糖呋喃糖作为糖基团的嘌呤N9-β-D-核苷酸,通过生物催化转基因嘌呤碱基和相应的3'-氨基-3'-脱氧尿苷、3'-氨基-3'-脱氧胸苷和2'-氨基-2'-脱氧尿苷作为碳水化合物基团供体,以大肠杆菌细胞作为生物催化剂或经戊二醛处理的大肠杆菌细胞作为生物催化剂或胸苷(尿苷)磷酸化酶和嘌呤核苷酸磷酸化酶的混合物进行合成。
  • OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE
    申请人:MANOHARAN Muthiah
    公开号:US20090281298A1
    公开(公告)日:2009-11-12
    One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.
    本发明的一个方面涉及至少包含一种非天然核碱基的双链寡核苷酸。在某些实施例中,非天然核碱基是二氟基甲苯基、硝基吲哚基、硝基吡咯基或硝基咪唑基。在一个首选实施例中,非天然核碱基是二氟基甲苯基。在某些实施例中,仅有双链寡核苷酸中的两个寡核苷酸链中的一个包含非天然核碱基。在某些实施例中,包含双链寡核苷酸的两个寡核苷酸链独立地包含非天然核碱基。在某些实施例中,寡核苷酸链包括至少一个修饰的糖基团。本发明的另一个方面涉及至少包含一种非天然核碱基的单链寡核苷酸。在一个首选实施例中,非天然核碱基是二氟基甲苯基。在某些实施例中,核苷中天然存在的核苷糖被替换为六碳糖、多环杂基烷基环或环己烯基团。在某些实施例中,寡核苷酸中的至少一个磷酸酯连接被替换为磷酸硫酯连接。
  • ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
    申请人:Moderna Therapeutics, Inc.
    公开号:US20150167017A1
    公开(公告)日:2015-06-18
    The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.
    本公开提供了替代核苷、核苷酸和核酸以及它们的使用方法。
  • REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS
    申请人:IONOVATION GMBH
    公开号:US20150240295A1
    公开(公告)日:2015-08-27
    The present invention relates to a method for the isolation and/or identification of known or unknown sequences of nucleic acids (target sequences) optionally marked with reporter groups by base specific hybridation with, essentially, complementary sequences (in the following referred to as sample oligo-nucleotides, sample sequences or sample nucleic acids), which belong to a library of sequences. Further, the invention relates to nucleolipids used in the method of the invention and a process for the preparation of said nucleolipids. In addition, the invention refers to a pharmaceutical composition comprising said nucleolipids.
    本发明涉及一种用于分离和/或识别已知或未知的核酸序列(目标序列)的方法,该方法可以通过与基本互补序列(以下称为样品寡核苷酸、样品序列或样品核酸)进行碱基特异性杂交来标记选定的序列(目标序列),这些序列属于序列库。此外,本发明涉及用于本发明方法的核脂质和制备该核脂质的过程。此外,本发明还涉及包含所述核脂质的制药组合物。
  • MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF
    申请人:MODERNA THERAPEUTICS, INC.
    公开号:US20150307542A1
    公开(公告)日:2015-10-29
    The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
    本公开提供了修改的核苷酸,核苷酸和核酸,以及使用它们的方法。
查看更多